China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical clearance from China’s National Medical Products Administration (NMPA) for its Category 1 chemical drug, SYH2062.
SYH2062: A Novel siRNA Therapy for Hypertension
SYH2062 is an N-acetyl-galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) that targets the inhibition of angiotensinogen (AGT) for the treatment of hypertension. This innovative product is designed to achieve a more durable gene silencing effect through optimized sequence and chemical modification strategies, potentially becoming a stable pressure control drug administered every 6 months.
Preclinical Studies Highlight SYH2062’s Long-Lasting Effects and Safety
Preclinical studies have demonstrated that the drug activity time of SYH2062 is significantly longer than that of similar siRNA products. This indicates differentiated advantages such as long-lasting drug effects, good safety, and high patient compliance. These characteristics position SYH2062 as a promising candidate in the treatment of hypertension, offering patients a potentially more convenient and effective therapy.-Fineline Info & Tech
